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Background: Curcumin inhibits growth of several cancer cell lines, and studies in this laboratory in bladder and
pancreatic cancer cells show that curcumin downregulates specificity protein (Sp) transcription factors Sp1, Sp3 and
Sp4 and pro-oncogenic Sp-regulated genes. In this study, we investigated the anticancer activity of curcumin and
several synthetic cyclohexanone and piperidine analogs in colon cancer cells.
Methods: The effects of curcumin and synthetic analogs on colon cancer cell proliferation and apoptosis were
determined using standardized assays. The changes in Sp proteins and Sp-regulated gene products were analysed
by western blots, and real time PCR was used to determine microRNA-27a (miR-27a), miR-20a, miR-17-5p and
ZBTB10 and ZBTB4 mRNA expression.
Results: The IC50 (half-maximal) values for growth inhibition (24 hr) of colon cancer cells by curcumin and synthetic
cyclohexanone and piperidine analogs of curcumin varied from 10 μM for curcumin to 0.7 μM for the most active
synthetic piperidine analog RL197, which was used along with curcumin as model agents in this study. Curcumin
and RL197 inhibited RKO and SW480 colon cancer cell growth and induced apoptosis, and this was accompanied
by downregulation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and Sp-regulated genes
including the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-MET), survivin,
bcl-2, cyclin D1 and NFκB (p65 and p50). Curcumin and RL197 also induced reactive oxygen species (ROS),
and cotreatment with the antioxidant glutathione significantly attenuated curcumin- and RL197-induced
growth inhibition and downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes. The mechanism of
curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of
the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that
regulate these repressors.
Conclusions: These results identify a new and highly potent curcumin derivative and demonstrate that in cells
where curcumin and RL197 induce ROS, an important underlying mechanism of action involves perturbation of
miR-ZBTB10/ZBTB4, resulting in the induction of these repressors which downregulate Sp transcription factors and
Sp-regulated genes.
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Traditional medicines have been extensively used for
treatment of multiple diseases including cancer, and many
widely used anticancer drugs are derived from natural
sources [1,2]. Curcumin is a major aromatic constituent of
turmeric (Curcuma longa) and has been widely investi-
gated for its anticancer activities in multiple cancer cell
lines and in vivo tumor models [3,4]. Curcumin has been
used in clinical trials for pancreatic cancer, and it is antici-
pated that curcumin or a suitable derivative will eventually
play a clinical role in cancer chemotherapy as a “stand
alone” drug or in combination therapies [5-9]. A major
problem associated with the use of curcumin is its low
bioavailability and this has resulted in efforts to improve
formulations for delivery of curcumin and also to develop
curcumin analogs that are more potent and more bioavail-
able [5,10-14].
The focus on curcumin as an anticancer agent is due,
in part, to its broad spectrum of activities. Curcumin
inhibits cancer cell and tumor growth, decreases sur-
vival, and inhibits angiogenesis and inflammation. Many,
but not all of these responses, are observed in different
cancer cell lines, and several pathways and genes respon-
sible for these effects have been reported [3,4]. For ex-
ample, curcumin-induced growth arrest and apoptosis in
various HCT-116-derived colon cancer cells was due to
induction of various caspases and inhibition of β-catenin
signaling pathways [15]. Other studies in colon cancer
cells report similar responses and also show downregula-
tion of cyclin D1, bcl-2, VEGF and p65 (NFΚB) and
other pro-oncogenic factors [15-19].
Studies in this laboratory have shown that curcumin
inhibits bladder and pancreatic cancer cell and tumor
growth and that the anticancer activity is due, in part, to
downregulation of specificity protein (Sp) transcription
factors Sp1, Sp3, Sp4 and Sp-regulated genes [20,21]. Sp
transcription factors are overexpressed in multiple can-
cer cell lines and tumors [20-26] and represent an ex-
ample of non-oncogene addiction by cancer cells
[27,28], and this is primarily due to the pro-oncogenic
activity of Sp-regulated genes. Results of drug (including
curcumin) treatment and Sp knockdown by RNA in-
terference have identified Sp-regulated genes that are
important for cell proliferation [cyclin D1, epidermal
growth factor receptor (EGFR), hepatocyte growth factor
receptor (c-MET)], survival (bcl-2, survivin), angiogen-
esis [vascular endothelial growth factor (VEGF) and its
receptors (VEGR)], and inflammation (p65 and p50)
[20-22,29-32]. In this study, we investigated the antican-
cer activities of curcumin and several synthetic analogs
using colon cancer cells as a model. Our major objec-
tives were to compare the relative potencies of curcumin
with the synthetic analogs, to determine their effects on
Sp transcription factors and Sp-regulated genes, and themechanisms responsible for downregulation of Sp tran-
scription factors.
Both curcumin and the most active synthetic analog
RL197 inhibited colon cancer cell growth with an IC50
(growth inhibition) of 10 and 0.7 μM, respectively. Both
compounds induced reactive oxygen species (ROS) and
downregulated Sp1, Sp3, Sp4 and Sp-regulated genes,
and these responses were attenuated by the antioxidant
glutathione (GSH). The mechanism of curcumin-/
RL197-induced repression of Sp transcription factors
was ROS-dependent and due to induction of the Sp
repressors ZBTB10 and ZBTB4 and downregulation of
microRNAs (miR)-27a, miR-20a and miR-17-5p that
regulate the repressors.
Methods
Cell lines, reagents and antibodies
RKO and SW480 human colon carcinoma cell lines and
CCD-18Co colon fibroblasts were obtained from
American Type Culture Collection (Manassas, VA). Cells
were initially grown and multiple aliquots were frozen and
stored at -80°C for future use. Cells were purchased more
than 6 months ago and were not further tested or authen-
ticated by the authors. Cells were maintained in
Dulbecco’s modified Eagle’s Medium (DMEM) with phe-
nol red supplemented with 10% FBS, and 10 mL/L of
100X antibiotic/antimycotic solution (Sigma-Aldrich Co.,
St. Louis, MO). Cells were cultured in 150-cm2 plates in
an air/CO2 (95:5) atmosphere at 37°C. All antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA) except c-MET and survivin (Cell Signaling Technol-
ogy, Danvers, MA), NFΚB-p50 and NFκB-p65 (Abcam
Inc., Cambridge, MA), Sp1 (Millipore, Billerica, MA), and
FAS (Sigma-Aldrich Co., St. Louis, MO). Glutathione, 98%
(γ-L-glutamyl-L-cysteinyl-glycine, GSH) and lactacystin
(proteasome inhibitor) were purchased from Sigma-
Aldrich. Carboxy-H2DCFDA was purchased from Invitro-
gen (Carlsbad, CA). Curcumin (98% pure) was purchased
from Indofine Chemical Company, Inc. (Hillsborough,
NJ), and curcumin analogs were synthesized as described
[14] and RL197 synthesis is outlined below.
Chemical synthesis
Melting points were determined on a Mettler Toledo
FP62 melting block and were uncorrected. High resolu-
tion mass spectrometry was recorded using a VG70-250S
double focusing magnetic sector mass spectrometer.
NMR spectra, at 25°C, were recorded at 500 MHz for 1H
and 125 MHz for 13C on Varian INOVA-500 spectrom-
eter. Chemical shifts are given in ppm on the δ scale
referenced to the solvent peaks CHCl3 at 7.26 and CDCl3
at 77.00. 1-Boc-4-piperidone, and 2,5-dimethoxybenzal-
dehyde were purchased from the Sigma-Aldrich Com-
pany. (3E,5E)-3,5-Bis(2,5-dimethoxybenzylidene)-1-t-
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mixture of 1-Boc-4-piperidone (0.70 g, 3.5 mmol) and
2,5-dimethoxybenzaldehyde (1.20 g, 7.4 mmol) in metha-
nol (50 mL) was added sodium methoxide (5M, 0.75 ml)
and the mixture was stirred for 18 hr at room
temperature. The resulting precipitate was removed by fil-
tration, then washed with cold methanol and purified by
recrystallisation from ethanol to give RL197 as a yellow
solid (1.20 g, 69%); mp 167.7°C. Found: C, 67.79; H, 6.79;
N, 2.73. C28H33NO7 requires: C, 67.86; H, 6.71; N, 2.83.
1H-NMR (CDCl3) δ: 1.26 (s, 9H), 3.79 (s, 6H), 3.82
(s, 6H), 4.59 (bs, 4H), 6.80 (bs, 2H), 6.85 (d, J = 9Hz, 2H),
6.89 (dd, J = 2, 9 Hz, 2H), 7.95 (bs, 2H); 13C-NMR
(CDCl3) δ: 187.76, 154.35, 153.05, 152.74, 133.30 (br),
124.83, 116.13, 115.46 (br), 111.80, 80.20, 56.04, 55.84,
45.05, 28.05: (HRMS (+ve ESI) calc for C28H33NaNO7:
518.2149 m/z [MNa+], found: 518.2115 m/z.
Cell proliferation assay and annexin V staining
RKO and SW480 cancer cells were seeded in DMEM
High Glucose with 10% FBS on 12-well plates and
allowed to attach for 24 hr. The medium was then chan-
ged to DMEM High Glucose containing 2.5% charcoal-
stripped FBS and cells were treated with either the ve-
hicle (DMSO) or the indicated compounds for 24 hr.
Cells were trypsinized and counted using a Coulter Z1
particle counter. For Annexin V staining, cells were
seeded in 6-well plates, allowed to attach overnight, and
treated with curcumin or RL197 as indicated. Annexin V
and propidium iodide staining was determined using the
Vybrant apoptosis assay kit #2 (Molecular Probes, Grand
Island, NY) and images were captured at 20X magnifica-
tion using IN cell analyzer 6000 (GE Healthcare Bios-
ciences, Piscataway, NJ).
Western blots
RKO and SW480 cancer cells were seeded in DMEM
High Glucose with 10% FBS on 6-well plates and
allowed to attach for 24 hr. The medium was then chan-
ged to DMEM High Glucose containing 2.5% charcoal-
stripped FBS and treated with either the vehicle (DMSO)
or the indicated compounds and analyzed by western
blots as described [20,21].
ROS estimation
Cellular ROS levels were evaluated with the cell per-
meant probe carboxy-H2DCFDA (5-(and-6)-carboxy-
20,70-dichlorodihydrofluorescein diacetate) from Invitro-
gen. Following treatment, cells seeded on 6-well plates
were loaded with 10 mM of carboxy-H2DCFDA for 1 hr,
washed once with serum-free medium, and analyzed for
ROS levels using BD Accuri C6 Flow Cytometer using
the FL1 channel. Analysis of data was determined with
BD Accuri CFlow software (set at 480 nm and 525 nmexcitation and emission wavelengths, respectively). Each
experiment was carried out in triplicate and results are
expressed as means ± S.E. for each treatment group.Measurement of mitochondrial membrane potential
(MMP)
MMP was measured with Mitochondrial Membrane Po-
tential Detection Kit (Stratagene, La Jolla, CA) according
to the manufacturer’s protocol using the JC-1 dye; mito-
chondrial membrane potential was measured using BD
Accuri C6 Flow Cytometer and data were analyzed using
the BD Accuri CFlow software. J-aggregates are detected
as red fluorescence and J-monomers are detected as
green fluorescence. Each experiment was determined in
triplicate, and results are expressed as means ± S.E. for
each treatment group.Quantitative real time PCR of mRNA and miRNAs
The mirVana miRNA Isolation Kit (Applied Biosystems,
Carlsbad, CA) was used for miRNA extraction and,
miRNAs (RNU6B, miRNA-27a, miRNA-20a, and
miRNA 17-5p) were quantitated by real time PCR
using the Taqman miRNA assay (Applied Biosystems)
according to the manufacturer’s protocol. U6 small nu-
clear RNA (RNU6B) was used as a control to deter-
mine relative miRNA expression. mRNA was extracted
using the RNeasy Protect Mini kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol, and
cDNA was prepared by reverse transcription using Re-
verse Transcription Kit (Promega, Madison, WI)
according to the manufacturer’s protocol. Each PCR
was carried out in triplicate using SYBR Green PCR
Master Mix (Invitrogen) at one cycle of 95°C for 10
min, 40 cycles of 95°C for 15 s, and 60°C for 1 min on
MyIQ2 Real Time PCR Detection System (BioRad,
Hercules, CA) with 1 μmol/L of each primer and 1 μL
cDNA template in each 20 μL reaction. TATA binding
protein (TBP) was used as an endogenous control to
compare the relative mRNA levels. Comparative CT
methods were used for relative quantitation of samples
and the following primers, purchased from Integrated
DNA Technologies (Coralville, IA ), were used:
Sp1 (Forward): 50-TCA CCT GCG GGC ACA CTT-30
Sp1 (Reverse): 50-CCG AAC GTG TGA AGC GTT-30
TBP (Forward): 50-TGCACAGGAGCCAAGAGTGAA-30
TBP (Reverse): 50-CACATCACAGCTCCCCACCA-30
ZBTB10 (Forward): 50-GCTGGATAGTAGTTATGTTGC-30
ZBTB10 (Reverse): 50-CTGAGTGGTTTGATGGACAGA-30
ZBTB4 (Forward): 50-ACCTGTGCAGGAATTTCCAC-30
ZBTB4 (Reverse): 50-GAGCGGCCAAGTTACTGAAG-30
Primers for Sp3 and Sp4 were purchased from Qiagen.
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Statistical significance of differences between the treatment
groups was determined using the Student’s t test, and levels
of probability were noted. IC50 values were calculated using
linear regression analysis and expressed in micromolar
(μM) concentrations at 95% confidence intervals.
Results
Curcumin inhibits colon cancer cell growth and
downregulates Sp transcription factors and Sp-regulated
genes
Curcumin induces a broad spectrum of anticancer activ-
ities in multiple cancer cell lines; however, the low bio-
availability of this compound has spurred interest inFigure 1 Structures of cyclohexanone (A) and piperidone (B) analogs
inhibition was determined as outlined in the Materials and Methods.development of different structural classes of analogs in-
cluding the heterocyclic and cyclohexanone derivatives
investigated in this study [13,14]. Figure 1 illustrates the
structures of these compounds and their respective IC50
values (half-maximal) for inhibition of RKO colon cancer
cell growth. The IC50 value for curcumin was 10 μM and
values for the 10 analogs ranged from 0.7 to 4.8 μM, with
the RL197 analog being the most potent compound. In
contrast, non-transformed CCD-18Co colon cells were
relatively resistant to the growth inhibitory effects of
RL197 and <30% growth inhibition was observed in cells
treated with 10 μM RL197 (Additional file 1: Figure S1A)
Figures 2A and 2B illustrate the concentration-dependent
inhibition of RKO and SW480 colon cancer cell growthand curcumin (C) and their growth inhibitory IC50 values. Growth
Figure 2 Curcumin and RL197 decrease RKO and SW480 cell growth and downregulate Sp1, Sp3 and Sp4 proteins. RKO (A) and SW480
(B) cells were treated with DMSO or different concentrations of curcumin and RL197, and after 24 hr, cell growth was determined as outlined in
the Materials and Methods. Results are means ± S.E. for at least 3 replicate determinations and significant (p < 0.05) inhibition compared to
DMSO (set at 100%) is indicated (*). Downregulation of Sp1, Sp3 and Sp4 proteins by different concentrations of curcumin (C) and RL197 (D)
(after 24 hr) in RKO and SW480 cells was determined by western blot analysis of whole cell lysates as described in the Materials and Methods.
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able effects were observed in both cell lines. Previous stud-
ies in this laboratory show that the anticancer activity of
curcumin is due, in part, to downregulation of Sp1, Sp3,
Sp4 and pro-oncogenic Sp-regulated genes [20,21], and
results in Figures 2C and 2D confirm that curcumin and
RL197 also decrease expression of Sp1, Sp3 and Sp4 pro-
teins in RKO and SW480 cells. We also examined the
effects of curcumin (Figures 3A and 3B) and RL197
(Figures 3C and 3D) on expression of several Sp-regulated
genes in RKO and SW480 cells, respectively. Both com-
pounds decreased levels of gene products that play roles
in cell proliferation (EGFR, cMET and cyclin D1), survival(survivin and bcl-2), inflammation (p65 and p50), and me-
tabolism/drug transport (fatty acid synthase (FAS)). In
addition, we also observed that curcumin and RL197
increased Annexin V staining (a marker of apoptosis) in
RKO and SW480 cells (Additional file 1: Figures S1B and
1C). These results are consistent with the effects of curcu-
min in other cell lines [20,21] where Sp transcription fac-
tors are an important target for this drug.
Curcumin and RL197 activate ROS in colon cancer cells
Drug-induced downregulation of Sp1, Sp3 and Sp4 is cell
context- and compound-dependent and involves activa-
tion of proteasomes or ROS [20,21,23,29,33-38]. Results
Figure 3 Curcumin and RL197 decrease expression of Sp-regulated gene products. Downregulation of Sp-regulated gene products by
different concentration of curcumin in RKO (A) and SW480 (B) cells, and by different concentrations of RL197 in RKO (C) and SW480 (D) cells was
determined by western blot analysis as described in the Materials and Methods. Experiments with Sp proteins (Figure 2) and Sp-regulated gene
products were part of the same study and have the same β-actin loading controls.
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curcumin- and RL197-mediated effects on Sp1, Sp3 and
Sp4 were not affected after cotreatment with the
proteasome inhibitor lactacystin in RKO and SW480 cells,
respectively. Moreover, in parallel experiments, lactacystin
did not affect curcumin- or RL197-mediated growth in-
hibition. Figures 4C and 4D show that curcumin- and
RL197-mediated downregulation of Sp transcription fac-
tors in RKO and SW480 cells, respectively, was attenuated
after cotreatment with the antioxidant GSH. These results
are comparable to those observed for curcumin in pancre-
atic cancer cells [21], suggesting that curcumin- and
RL197-dependent effects on Sp1, Sp3 and Sp4 are ROS-
dependent.
RKO cells were used as a model to investigate induc-
tion of ROS and its role in mediating the effects ofcurcumin and RL197. Figures 5A and 5B show that both
curcumin and RL197 significantly induced ROS forma-
tion after treatment for 24 and 18 hr, respectively, and
this response was attenuated after cotreatment with the
antioxidant GSH. The magnitude of ROS induction by
curcumin was much higher than observed for RL197,
and induction of ROS by RL197 was minimal at all time
points ≤ 18 hr. In contrast, curcumin significantly
induced ROS in RKO cells after treatment for 6, 12, 18
and 24 hr (Additional file 2: Figure S2). Curcumin and
RL197 decreased MMP in RKO cells and this response
was also attenuated after cotreatment with GSH
(Figure 5C). These results suggest that RL197 directly
effects mitochondria resulting in ROS production,
whereas the parallel induction of ROS and decreased
MMP observed after treatment with curcumin is
Figure 4 (See legend on next page.)
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Figure 4 Curcumin and RL197-mediated activation of proteasomes and ROS. RKO (A) and SW480 (B) cells were treated with DMSO
(control), curcumin, or RL197 alone or in combination with 1 μM lactacystin for 24 hr ,and effects on cell proliferation or expression of Sp1, Sp3 or
Sp4 proteins (western blots) were determined as outlined in the Materials and Methods. RKO (C) and SW480 (D) cells were treated with DMSO,
curcumin, RL197 alone or in combination with 5 mM GSH for 24 hr, and whole cell lysates were analyzed by western blot analysis as described in
the Materials and Methods. Cell proliferation results (A, B) are means ± S.E. for at least 3 replicate experiments, and significant (p < 0.05) growth
inhibition is indicated (*).
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duction involving extramitochondrial pathways, and this
is currently being investigated. Despite differences in the
magnitude and mechanisms of ROS induction by curcu-
min and RL197, their effects on RKO cell growth inhib-
ition were also inhibited after cotreatment with GSH
(Figure 5D), confirming the critical role of ROS in medi-
ating the cytotoxicity of curcumin and RL197 in colon
cancer cells. We also observed that 5 mM GSH alone
slightly inhibited RKO cell proliferation; however, a
<25% decrease in growth was observed (Figure 5D).
Curcumin and RL197 disrupt miR27a:ZBTB10 and miR-
20a/17-5p:ZBTB4 interactions
ZBTB10 is a transcriptional “Sp repressor” regulated by
miR-27a in cancer cell lines, and previous studies show
that drug-induced Sp repression is due to ROS-
dependent disruption of miR-27a:ZBTB10 [29,34,38].
Treatment of RKO cells with curcumin or RL197
induced expression of ZBTB10 and this was attenuated
after cotreatment with GSH. A recent report identified
ZBTB4 as a second “Sp repressor” [26], and we also
observed that curcumin and RL197 induced ZBTB4 ex-
pression and this was partially inhibited after cotreat-
ment with GSH (Figure 6A). Curcumin and RL197
decreased expression of miR-27a [25] and also miR-20a/
miR-17-5p which regulate (inhibit) expression of
ZBTB10 and ZBTB4, respectively [26], and these
responses were also inhibited after cotreatment with
GSH (Figure 6B). The induction of the transcriptional
repressors ZBTB10 and ZBTB4 was accompanied by
decreased expression of Sp1, Sp3 and Sp4 mRNA levels
(Figure 6C) and their corresponding proteins (Figure 2).
These results suggest a mechanism of action of curcu-
min and RL197 which is illustrated in Figure 6D. Induc-
tion of ROS by curcumin and RL197 results in ROS-
dependent disruption of miR-ZBTB10 and miR-ZBTB4
and the subsequent induction of the transcriptional
repressors results in suppression of genes with GC-rich
promoters, including Sp1, Sp3, Sp4 and Sp-regulated
genes.
Discussion
Non-oncogene addiction by cancer cells is now recog-
nized as an important pathway for maintaining the can-
cer cell phenotype [27,28] and Sp transcription factorsare an example of non-oncogenes that fulfill this func-
tion. Sp1, Sp3 and Sp4 are overexpressed in multiple
cancer cell lines and tumor types and Sp-regulated genes
and oncogenes play an important role in cancer cell
proliferation, survival, angiogenesis and inflammation
[20-26,29-38]. These transcription factors are ideal for
development of mechanism-based drugs since Sp1 ex-
pression decreases with age [39-41], and results of ani-
mal studies show that Sp1, Sp3 and Sp4 are highly
expressed in tumor but not in non-tumor tissues
[21,23]. The high expression of Sp transcription factors
is due, in part, to miR-dependent repression of the Sp
repressors ZBTB10 and ZBTB4, which competitively
bind GC-rich gene promoters and deactivate transcrip-
tion [25,26]. MiR-27a and miRs-20a/17-5p, which are
overexpressed in many tumors interact with and sup-
press ZBTB10 or ZBTB4, respectively, and overexpres-
sion of ZBTB10 and ZBTB4 or transfection of cells with
miR-27a and miR-20a/17-5p antagomirs also decrease
expression of Sp transcription factors [25,26].
Several drugs that target Sp transcription factors
have been identified and these include the non-
steroidal anti-inflammatory drugs (NSAIDs) tolfenamic
acid, COX-2 inhibitors and the nitro-NSAID GT-094,
and several natural products including betulinic acid
(BA), celastrol and the synthetic triterpenoids methyl
2-cyano-3,12-dioxooleana-a-dien-28-oate (CDDO-Me)
and methyl 2-cyano-3,4-dioxo-18β-olean-1,12-dien-30-
oate (CDODA-Me) [20-26,29-38]. In bladder cancer
cells, curcumin induced proteasome-dependent down-
regulation of Sp1, Sp3 and Sp4 [20], whereas in pan-
creatic cancer cells this response was ROS-dependent
and reversed by cotreatment with antioxidants such as
GSH [21]. Both curcumin and the potent RL197 ana-
log induced ROS (Figure 5A) and decreased expression
of Sp1, Sp3, Sp4 and Sp-regulated proteins (Figures 2
and 3) in colon cancer cells, and cotreatment with
GSH inhibited these responses and also partially
reversed the growth inhibitory effects of these com-
pounds (Figure 5D). Similar effects have previously
been observed for BA and GT-094 in colon cancer
cells and induction of ROS is also a critical element
for their cytotoxicity [34,35]. However, the identities of
individual ROS species induced by curcumin and
RL197 have not been determined and are currently
being investigated.
Figure 5 The antioxidant GSH attenuates curcumin and RL197-induced responses. RKO cells were treated with curcumin and RL197 for 24
(A) or 18 (B) hr, and induction of ROS was investigated by FACS analysis as outlined in the Materials and Methods. RKO cells were treated with
DMSO, curcumin, and RL197 alone and in combination with GSH for 12 (C) or 24 (D) hr, and effects on MMP or cell proliferation, respectively,
were determined as outlined in the Materials and Methods. Results are means ± S.E. for at least 3 replicate determinations, and significant
(p < 0.05) induction of ROS, MMP or cell proliferation (*) and inhibition after cotreatment with GSH (**) is indicated.
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Figure 6 Curcumin and RL197 disrupt miR-ZBTB10/ZBTB4 interactions. RKO cells were treated with DMSO, curcumin, and RL197 alone or in
combination with GSH, and induction of ZBTB10 or ZBTB4 (A) and downregulation of multiple miRs (B) were determined by real time PCR as
outlined in the Materials and Methods. Results are means ± S.E. for at least 3 replicate determinations and significant (p < 0.05) induction of
ZBTB10 or ZBTB4 and suppression of miRs (*) and inhibition of these responses by GSH (**) are indicated. (C) Curcumin and RL197-dependent
downregulation of Sp1, Sp3 and Sp4 mRNA levels was determined in RKO cells as outlined in the Materials and Methods. Results are means ± S.E.
(3 replicates) and significant (p < 0.05) inhibition is indicated. (D) Proposed mechanism of action of curcumin and RL197 in RKO cells.
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several factors including oxidative DNA damage; how-
ever, several anticancer drugs also induce ROS and this
plays an important role in their cancer chemotherapeu-
tic activity [42,43]. Induction of ROS by CDDO-Me, BA/
GT-094 and celastrol in pancreatic, colon and bladder
cancer cells, respectively, results in downregulation of
miR-27a and induction of ZBTB10 [29,34,35]. Moreover,
celastrol also downregulates miR-20a and other miR
paralogs with the same seed sequence in bladder cancer
cells and this is accompanied by induction of ZBTB4.
This study demonstrates that like celastrol, curcumin-
and RL197-induced ROS in RKO cells also decreases
miR-dependent regulation of ZBTB10 and ZBTB4
(Figure 6). Previous studies show that curcumin induces
ROS in some cancer cell lines [44-48], and results of this
study suggest that curcumin and RL197 induce ROS in
RKO cells and ROS-mediated disruption of miR-ZBTB
interactions results in downregulation of Sp transcrip-
tion factors and Sp-regulated gene products. These
results for curcumin and RL197 in colon cancer cells are
consistent with previous studies with other ROS indu-
cers which act as anticancer agents through the com-
mon pathway illustrated in Figure 6D.
Conclusions
Previous reports show that the many anticancer agents
such as curcumin and RL197 target Sp transcription fac-
tors and Sp-regulated genes [20-26,30-38] and thereby
inhibit non-oncogene addiction by cancer cells and
tumors. The mechanisms of Sp downregulation are both
drug- and cell context-dependent, and this study
demonstrates the important role of ROS in disrupting
miR-mediated suppression of ZBTB10 and ZBTB4.
Current studies are focused on the critical trans-acting
factors that are induced or inhibited by ROS and are
required to decrease miR-27a and miR-20a/17-5p ex-
pression and possibly other miRs that form part of the
miR-23a~miR-27a~miR-24-2 and miR-17-92 clusters,
respectively.
Additional files
Additional file 1: Figure S1. Effects of RL197 on proliferation of CCD-
18Co colon fibroblasts (A) and induction of Annexin V staining by
curcumin and RL197 in RKO (B) and SW480 (C) colon cancer cells.
Additional file 2: Figure S2. ROS induction by curcumin. RKO cells
were treated with 20 or 30 μM curcumin alone or with GSH. ROS was
determined 6, 12, 18 or 24 hr after treatment by FACS analysis as
outlined in the Materials and Methods.
Abbreviations
BA: Betulinic acid; CB: Cannabinoid; CDDO: 2-cyano-3,12-dioxoolean-1,9-dien-
28-oic acid; CDODA: 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oic acid;
c-MET: Hepatocyte growth factor receptor; EGFR: Epidermal growth factor
receptor; FAAH: Fatty acid amide hydrolase; ROS: Reactive oxygen species;siRNA: Small inhibitory RNA; Sp: Specificity protein; VEGF: Vascular endothelial
growth factor; VEGFR: Vascular endothelial growth factor receptor.
Competing interests
The authors declare they have no competing interests.
Author’s contributions
SUG carried out the majority of the in vitro studies, analyzed and
summarized the results, and helped draft this manuscript. KK co-supervised
research and carried out PCR studies on miR expression. LL and RJR
synthesized compounds and helped with drafting of this manuscript. SS
conceived of this project, wrote the manuscript, and supervised research. All
authors read and approved the final manuscript.
Acknowledgements
National Institutes of Health (R01-CA136571) and Texas AgriLife.The authors
would like to thank Gayathri Chadalapaka and Ping Lei for their help.
Author details
1College of Medicine, Texas A&M Health Sciences Center, Houston, TX 77030,
USA. 2Institute of Biosciences and Technology, Texas A&M Health Science
Center, 2121 W. Holcombe Blvd, Houston, TX 77030, USA. 3Department of
Chemistry, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.
4Department of Pharmacology and Toxicology, University of Otago, P.O. Box
913, Dunedin 9054, New Zealand. 5Department of Veterinary Physiology and
Pharmacology, Texas A&M University, 4466 TAMU, College Station, TX
77843-4466, USA.
Received: 13 April 2012 Accepted: 23 November 2012
Published: 30 November 2012
References
1. Koehn FE, Carter GT: The evolving role of natural products in drug
discovery. Nat Rev Drug Discov 2005, 4:206–220.
2. Butler MS: The role of natural product chemistry in drug discovery.
J Nat Prod 2004, 67:2141–2153.
3. Aggarwal BB, Shishodia S: Molecular targets of dietary agents for
prevention and therapy of cancer. Biochem Pharmacol 2006,
71:1397–1421.
4. Gupta SC, Kim JH, Prasad S, Aggarwal BB: Regulation of survival,
proliferation, invasion, angiogenesis, and metastasis of tumor cells
through modulation of inflammatory pathways by nutraceuticals.
Cancer Metastasis Rev 2010, 29:405–434.
5. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM,
Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP: Pharmacodynamic
and pharmacokinetic study of oral Curcuma extract in patients with
colorectal cancer. Clin Cancer Res 2001, 7:1894–1900.
6. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR,
Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al: Phase I clinical
trial of oral curcumin: biomarkers of systemic activity and compliance.
Clin Cancer Res 2004, 10:6847–6854.
7. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB,
Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin
in patients with advanced pancreatic cancer. Clin Cancer Res 2008,
14:4491–4499.
8. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin:
preclinical and clinical studies. Anticancer Res 2003, 23:363–398.
9. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR,
Ming-Shiang W, et al: Phase I clinical trial of curcumin, a
chemopreventive agent, in patients with high-risk or pre-malignant
lesions. Anticancer Res 2001, 21:2895–2900.
10. Li L, Ahmed B, Mehta K, Kurzrock R: Liposomal curcumin with and without
oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in
colorectal cancer. Mol Cancer Ther 2007, 6:1276–1282.
11. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P,
Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, et al: Diphenyl
difluoroketone: a curcumin derivative with potent in vivo anticancer
activity. Cancer Res 2008, 68:1962–1969.
12. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A,
Takahashi S, Kato S, Suzuki T, Ishioka C, et al: Synthesis and biological
Gandhy et al. BMC Cancer 2012, 12:564 Page 12 of 12
http://www.biomedcentral.com/1471-2407/12/564analysis of new curcumin analogues bearing an enhanced potential for
the medicinal treatment of cancer. Mol Cancer Ther 2006, 5:2563–2571.
13. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren
RJ: Mechanisms for the activity of heterocyclic cyclohexanone curcumin
derivatives in estrogen receptor negative human breast cancer cell lines.
Invest New Drugs 2011, 29:87–97.
14. Yadav B, Taurin S, Rosengren RJ, Schumacher M, Diederich M,
Somers-Edgar TJ, Larsen L: Synthesis and cytotoxic potential of
heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem
2010, 18:6701–6707.
15. Jaiswal AS, Marlow BP, Gupta N, Narayan S: Beta-catenin-mediated
transactivation and cell-cell adhesion pathways are important in
curcumin (diferuylmethane)-induced growth arrest and apoptosis in
colon cancer cells. Oncogene 2002, 21:8414–8427.
16. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A,
Gelovani J, Guha S, Krishnan S, Aggarwal BB: Curcumin sensitizes human
colorectal cancer to capecitabine by modulation of cyclin D1, COX-2,
MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Int J Cancer 2009, 125:2187–2197.
17. Sandur SK, Deorukhkar A, Pandey MK, Pabon AM, Shentu S, Guha S,
Aggarwal BB, Krishnan S: Curcumin modulates the radiosensitivity of
colorectal cancer cells by suppressing constitutive and inducible
NF-kappaB activity. Int J Radiat Oncol Biol Phys 2009, 75:534–542.
18. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP:
Curcumin inhibits the proteasome activity in human colon cancer cells
in vitro and in vivo. Cancer Res 2008, 68:7283–7292.
19. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar AP:
Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in
mediating growth inhibition of colon cancer cells by modulating EGFR
and IGF-1R. Int J Cancer 2008, 122:267–273.
20. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R III, Li X, Safe
S: Curcumin decreases specificity protein expression in bladder cancer
cells. Cancer Res 2008, 68:5345–5354.
21. Jutooru I, Chadalapaka G, Lei P, Safe S: Inhibition of NFkB and pancreatic
cancer cell and tumor growth by curcumin is dependent on specificity
protein down-regulation. J Biol Chem 2010, 285:25332–25344.
22. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L,
Safe S: Inhibition of pituitary tumor-transforming gene-1 in thyroid
cancer cells by drugs that decrease specificity proteins. Mol Carcinog
2011, 50:655–667.
23. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S: Betulinic acid inhibits
prostate cancer growth through inhibition of specificity protein
transcription factors. Cancer Res 2007, 67:2816–2823.
24. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R,
Abudayyeh A, Baker C, Herrera L, Safe S: Tolfenamic acid inhibits
esophageal cancer through repression of specificity proteins and c-Met.
Carcinogenesis 2009, 30:1193–1201.
25. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S: The oncogenic
microRNA-27a targets genes that regulate specificity protein
transcription factors and the G2-M checkpoint in MDA-MB-231 breast
cancer cells. Cancer Res 2007, 67:11001–11011.
26. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park
YY, Lee JS, Safe S: Identification of oncogenic microRNA-17-92/ZBTB4/
specificity protein axis in breast cancer. Oncogene 2011, 31:1034–1044.
27. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and
non-oncogene addiction. Cell 2009, 136:823–837.
28. Torti D, Trusolino L: Oncogene addiction as a foundational rationale for
targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011,
3:623–636.
29. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva
M, Andreeff M, Safe S: Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate
decreases specificity protein transcription factors and inhibits pancreatic
tumor growth: role of microRNA-27a. Mol Pharmacol 2010, 78:226–236.
30. Abdelrahim M, Smith R III, Burghardt R, Safe S: Role of Sp proteins in
regulation of vascular endothelial growth factor expression and
proliferation of pancreatic cancer cells. Cancer Res 2004, 64:6740–6749.
31. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S: Regulation of vascular
endothelial growth factor receptor-2 expression in pancreatic cancer
cells by Sp proteins. Biochem Biophys Res Commun 2006, 345:292–301.32. Chadalapaka G, Jutooru I, Burghardt R, Safe S: Drugs that target specificity
proteins downregulate epidermal growth factor receptor in bladder
cancer cells. Mol Cancer Res 2010, 8:739–750.
33. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S: Tolfenamic acid and
pancreatic cancer growth, angiogenesis, and Sp protein degradation.
J Natl Cancer Inst 2006, 98:855–868.
34. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, Safe
S: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of
a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein
pathway. Mol Cancer Res 2011, 9:195–202.
35. Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S: Betulinic acid inhibits
colon cancer cell and tumor growth and induces proteasome-
dependent and -independent downregulation of specificity proteins (Sp)
transcription factors. BMC Cancer 2011, 11:371.
36. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe
S: Arsenic trioxide downregulates specificity protein (Sp) transcription
factors and inhibits bladder cancer cell and tumor growth.
Exp Cell Res 2010, 316:2174–2188.
37. Pathi SS, Lei P, Sreevalsan S, Chadalapaka G, Jutooru I, Safe S:
Pharmacologic doses of ascorbic acid repress specificity protein (Sp)
transcription factors and Sp-regulated genes in colon cancer cells.
Nutr Cancer 2011, 63:1133–1142.
38. Chadalapaka G, Jutooru I, Safe S: elastrol decreases specificity proteins
(Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer
cells. Carcinogenesis 2012, 33:886–894.
39. Ammendola R, Mesuraca M, Russo T, Cimino F: Sp1 DNA binding efficiency
is highly reduced in nuclear extracts from aged rat tissues.
J Biol Chem 1992, 267:17944–17948.
40. Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, Herbert DC, Walter CA,
Weaker FJ, Bowman BH: YY1 and Sp1 transcription factors bind the
human transferrin gene in an age-related manner. J Gerontol A Biol Sci
Med Sci 1996, 51:B66–B75.
41. Oh JE, Han JA, Hwang ES: Downregulation of transcription factor, Sp1,
during cellular senescence. Biochem Biophys Res Commun 2007, 353:86–91.
42. Fruehauf JP, Meyskens FL Jr: Reactive oxygen species: a breath of life or
death? Clin Cancer Res 2007, 13:789–794.
43. Trachootham D, Alexandre J, Huang P: Targeting cancer cells by
ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev
Drug Discov 2009, 8:579–591.
44. Kim KC, Lee C: Curcumin Induces Downregulation of E2F4 Expression
and Apoptotic Cell Death in HCT116 Human Colon Cancer Cells;
Involvement of Reactive Oxygen Species. Korean J Physiol Pharmacol 2010,
14:391–397.
45. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong
YJ, Lee YH, et al: Molecular mechanisms of curcumin-induced
cytotoxicity: induction of apoptosis through generation of reactive
oxygen species, down-regulation of Bcl-XL and IAP, the release of
cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24:1199–1208.
46. Hilchie AL, Furlong SJ, Sutton K, Richardson A, Robichaud MR,
Giacomantonio CA, Ridgway ND, Hoskin DW: Curcumin-induced apoptosis
in PC3 prostate carcinoma cells is caspase-independent and involves
cellular ceramide accumulation and damage to mitochondria.
Nutr Cancer 2010, 62:379–389.
47. Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S: Rapid reactive
oxygen species (ROS) generation induced by curcumin leads to caspase-
dependent and -independent apoptosis in L929 cells. Free Radic Biol Med
2008, 45:1403–1412.
48. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A: Curcumin
mediated apoptosis in AK-5 tumor cells involves the production of
reactive oxygen intermediates. FEBS Lett 1999, 456:311–314.
doi:10.1186/1471-2407-12-564
Cite this article as: Gandhy et al.: Curcumin and synthetic analogs
induce reactive oxygen species and decreases specificity protein (Sp)
transcription factors by targeting microRNAs. BMC Cancer 2012 12:564.
